• Head CTs, MRIs are most-used but not most-effective tool for head trauma or neurological issues in triage
• EEG changed clinical management of 76.2% of patients, even when CT or MRI was available
• Brain Scientific has overcome key barriers causing EEG underuse in emergency medicine

Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company, is making EEGs accessible in emergency departments (“ED”) with cutting-edge tech that bridges the widening gap in access to quality care. As the public becomes more aware of head trauma’s long-term effects, triages fill up with potential TBIs and acute neurological conditions. Facilities are scrambling to adapt to the growing need but are often ill equipped to do so.

When a patient arrives presenting head trauma or neurological issues, almost reflexively, a head CT and/or MRI is ordered. A BRSF white paper titled “Electroencephalography in the Emergency Department” explains why this is not always the most effective diagnostic tool (https://ibn.fm/IWTxt).

The report notes that head CT is not always the optimal scan for all acute neurological conditions; however, due to its availability, it is overused. Around 70 million CT examinations are performed in EDs annually in the United States (https://ibn.fm/gwcGo). While these are ideal for brain hemorrhage, skull fractures, malignancy and a handful of other conditions, they have been found ineffective at identifying mild traumatic brain injury (“mTBI”) and nontraumatic causes of neurologic dysfunction such as syncope, delirium, and vertigo. The MRI provides higher resolution images and greater detail of the brain than the CT but is limited as a primary diagnostic tool in the ED.

According to the CDC, an estimated 2.5 million TBI-related visits are made to the ED in the U.S. a year (https://ibn.fm/cppKg). Part of the increase is due to the public’s growing knowledge of TBI effects. Neither the head CT or MRI are equipped to diagnose mTBI adequately. The best indicator is an EEG, which can determine the severity of the injury.

Delirium is also often seen in the ED and can affect up to one-half of older patients in hospitals. However, experiencing delirium in a hospital setting does not mean a patient has Alzheimer’s or another dementia diagnosis. Dementia is chronic, while delirium is usually reversible. Determining what the patient is experiencing is essential in creating a successful care plan. An EEG can make this distinction.

The American Academy of Neurology published a study on routine EEGs in emergency room and inpatient services. It was found that the use of the EEG changed the clinical management of 76.2% of patients, even when a normal CT or MRI was available (https://ibn.fm/gCNV4).

Beyond TBIs and dementia, EEGs are also used to diagnose epilepsy and other acute neurological conditions that CTs and MRIs are simply not designed to find.

So why are EEGs not used more often?

The size of traditional EEG systems, lack of portability and inadequate numbers of trained EEG personnel are key factors contributing to the underuse of the EEG in emergency medicine. Utilizing equipment that takes hours is not feasible in a triage situation. Brain Scientific has overcome these barriers with two separate devices: the NeuroCap(TM) and NeuroEEG(TM). Low cost, portable, small, wireless, and easy to set up, these devices make it possible for EEGs to be utilized in emergency departments across the country.

To learn more about this company, visit www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• POAI completes two separate fundraising initiatives: private placement, direct offering.
• Two fundraising campaigns expected to result in $17.6 million, $7.4 million respectively.
• Predictive Oncology plans to use funds to pay off debt as well as for working capital, general corporate purposes.

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced two funding initiatives that together total an estimated $25 million. The company has entered into securities purchase agreements with institutional and accredited investors (https://ibn.fm/WH4nw) to raise approximately $17.6 million and is involved in a direct offering that is expected to raise $7.4 million (https://ibn.fm/uSv23).

The securities purchase agreement was comprised of a total of 9,043,766 shares of common stock and warrants, offered at a purchase price of $1.95 per share. The private placement was expected to close around Feb. 22, 2021. In the announcement of the private placement, Predictive Oncology noted that it planned to use some $5.88 million of the net proceeds from the placement to pay off debt; the company has earmarked the remaining funds for general corporate purposes.

The direct offering is also between POAI and select institutional and accredited investors. Consisting of approximately 4,222,288 shares of common stock offered at a purchase price of $1.75 per share, the offering was expected to close approximately Feb. 26, 2021. The company noted that it plans to use the $7.4 million net proceeds from this placement for working capital purposes.

In the past, the pharmaceutical industry has invested heavily in genomics and big data, hoping to better understand individual patient’s genomes and deliver targeted therapeutics. In reality, the use of genomics alone has proven to be disappointing. Predictive Oncology is confident that a multi-omic approach offers much greater chance of success. Unfortunately, few comprehensive, multi-omic datasets exist, and such data is difficult to access quickly as it is both costly and time consuming to initiate prospective data collection – especially in cancer, an area where Predictive Oncology is focused.

POAI, however, is a leader in the nascent multi-omic game. The company has spent years gathering an estimated 150,000 clinically validated cases on its molecular information platform, with more than 38,000 of those specific to ovarian cancer. The data in POAI’s molecular information platform are highly differentiated, having both drug response data and access to historical outcome data from those patient samples. Predictive Oncology is focused on generating additional sequence data from these tumor samples to deliver on the unmet market need across the pharmaceutical industry for a multi-omic approach to new drug development and, most importantly, improved patient outcomes. The recently acquired funds will go far in assuring the progress of this work.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Increased nuclear power projects fueling rising demand for uranium
• UEC controls one of the largest historical uranium exploration and development databases in United States
• UEC property portfolio includes properties previously explored and developed by senior energy firms
• UEC has fully licensed, low cost, ISR projects positioned to supply the U.S. Uranium Reserve
• Nuclear energy included in Democratic Party’s energy platform for first time in 48 years

After spending a solid ten years in a downward trend, uranium stocks are now making fresh 52-week highs amid increased demand for energy (https://ibn.fm/GXF7e). Uranium Energy (NYSE American: UEC), a U.S.-based uranium mining and exploration company that controls one of the largest historical uranium exploration and development databases in the United States, is positioned to benefit from the trend after having acquired multiple mining sites in North and South America that allow the company to target specific uranium-rich areas.

Increased global demand for nuclear energy continues to drive the demand for uranium while long-term supplies are becoming less certain. Analyst Lyn Alden Schwartzer of Seeking Alpha predicts robust and increasing demand for uranium from developing nations and manufacturing powerhouses like China that continue to increase nuclear power consumption (https://ibn.fm/EI3BY). With lead times for new production spanning between seven to ten years or longer, current prices are not yet at levels that incentivize future production, further exacerbating longer-term supply concerns. Despite these conditions, uranium’s spot price is currently less than its production cost for most Western producers, signaling potential opportunities for suppliers and investors.

UEC controls one of the largest historical uranium exploration and development databases in the United States with properties in various locations, including Texas, New Mexico, Colorado, Arizona and Wyoming. The company’s use of historical exploration data has enabled it to target and acquire properties that have already been explored and developed by senior energy firms in the past, in some cases spending as much as $50 million to develop individual projects.

Since inception in 2005, UEC’s main strategic focus has been on acquiring and developing U.S. in-situ recovery (“ISR”) projects that are an environmentally friendly and lower-cost alternative to conventional mining. The Company has a near-term extraction profile of 4 million pounds of U3O8 per year from its south Texas and Wyoming ISR projects.

Long-term fundamentals underlying the uranium market continue to strengthen. Projections from industry analysts reveal annual deficits between production and utility requirements of about 40 million pounds well into 2026, with the gap approaching almost 70 million pounds per year by 2030.

With its fully licensed, low-cost U.S. ISR projects, UEC is also very well positioned to participate in the United States strategic uranium reserve. The uranium reserve budget is $1.5 billion over ten years for domestic uranium and conversion, with initial funding of $75 million approved by Congress for fiscal 2021. While predicted demand for uranium plays strongly into analysts’ forecasts, optimism is further bolstered by bipartisan support for nuclear energy that includes its inclusion into the Democratic Party’s energy platform for the first time in 48 years.

Uranium Energy Corp is a U.S.-based uranium mining and exploration company. In South Texas, the Company’s hub-and-spoke operations are anchored by the fully-licensed Hobson Processing Facility, which is central to the Palangana, Burke Hollow and Goliad ISR projects. In Wyoming, UEC controls the Reno Creek project, which is the largest permitted, pre-construction ISR uranium project in the U.S. Additionally, the Company controls a pipeline of uranium projects in Arizona, New Mexico and Paraguay, a uranium/vanadium project in Colorado and a large, high-grade ferro-titanium project in Paraguay. The Company’s operations are managed by professionals with a recognized profile for excellence in their industry, a profile based on many decades of hands-on experience in the key facets of uranium exploration, development and mining.

For more information on Uranium Energy Corp., visit the company’s website at www.UraniumEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to UEC are available in the company’s newsroom at https://ibn.fm/UEC

• CNS Pharmaceuticals holds the exclusive worldwide license to the Berubicin chemical compound
• Berubicin is CNSP’s lead, novel anthracycline candidate for the treatment of glioblastoma multiforme (“GBM”) that was the subject of a previously conducted Phase 1 clinical trial, which had a clinical benefit response rate of 44%
• CNSP has sublicensed Berubicin to WPD Pharmaceuticals in 31 countries primarily in eastern Europe and western Asia
• WPD plans to conduct a Phase 2 trial in adults with GBM and a Phase 1 trial for pediatric patients with malignant gliomas
• CNSP intends to conduct its own Phase 2, potentially pivotal, trial in s GBM patients who have failed first-line therapy and is on track to commence the study in March 2021
• Both WPD and CNSP have received favorable opinions for their respective protocols to be used in their clinical trials

The Lower Silesian Medical Chamber Ethics Committee in Wroclaw, Poland recently gave WPD Pharmaceuticals (CSE: WBIO) (Frankfurt: 8SV1) (“WPD”), CNS Pharmaceuticals, Inc.’s (NASDAQ: CNSP) sublicensee in Europe and Asia for Berubicin, a positive opinion for its WPD-201 Clinical Trial Protocol to be used in the planned forthcoming Berubicin clinical trial in adults with glioblastoma multiforme (“GBM”).

Notably, a regulatory body within a given territory – in this case, Poland – shares a positive opinion to ascertain that a study, through its protocol, respects participants’ dignity, rights, safety, and well-being.

This new development, which CNSP and WPD announced in a news release recently, set the wheels in motion for the eventual approval of WPD’s studies – a multicenter Berubicin Phase 2 adult GBM trial and a multicenter pediatric Phase 1 malignant glioma trial.

“This is an important step for WPD,” commented Mariusz Olejniczak, WPD’s CEO (https://ibn.fm/PH9lC). “From both a project and sublicense agreement point of view. After receiving the Central Ethics Committee’s positive opinion, we are planning to submit our application to the Office for Registration of Medical Products, Medical Devices, and Biocidal Products, which is the Polish equivalent of the FDA. We hope to receive an approval within three months from submission.”

WPD plans to start the Phase 2 trial in the first half of 2021 and the Phase 1 trial later in 2021. This will bring the total number of Berubicin clinical trials to be started in 2021 to three as CNSP will also conduct its Phase 2 trial. CNSP’s Phase 2 trial will evaluate the efficiency and safety of Berubicin as a treatment for adults with GBM who have failed first-line therapy.

CNSP slated its study for March= 2021, having received approval from the U.S. Food and Drug Administration (“FDA”) for its Investigational New Drug (“IND”) application and a study level Central IRB approval from the Central IRB for the CNS-201 Clinical Trial Protocol.

“We are pleased for WPD to achieve this key milestone and are encouraged by their continued execution in furthering the development of Berubicin,” John Climaco, the CEO of CNS Pharmaceuticals, said. “We look forward to continuing our trial preparations, as well as WPD’s planned submissions to the Polish Competent Authority”.

Berubicin is CNSP’s novel anthracycline (a chemotherapy drug), which is notably unique from other anthracyclines. Historically, anthracyclines have never been used to treat primary or metastatic brain cancers because they did not have any demonstratable ability to cross the blood-brain barrier and achieve significant levels of activity in the brain. However, based on limited available data, it appears that Berubicin can cross the barrier (https://ibn.fm/JHtMJ).

Its efficacy was demonstrated in Phase 1 clinical trial completed in 2006 by Reata Pharmaceuticals, Inc. – CNSP has since acquired all the data from this trial and is currently the exclusive Berubicin license holder, subject to the sublicense agreement with WPD. The Phase 1 trial, which has 25 participants evaluable, had an overall response rate (clinical benefit of stable disease or better) of 44%. Notably, one patient’s experience with the treatment was durable as they have remained cancer-free for well over a decade through the most recent clinical evaluation on November 6, 2020. The Phase 1 trial had a limited sample size, so there can be no guarantee that similar results will be realized in the subsequent trials, but it is promising. CNSP’s Phase 2 trial will have an estimated enrollment of over 200 participants (https://ibn.fm/C6426).

CNSP is a clinical-stage biotechnology company that focuses on developing new treatments for the brain and central nervous system’s primary and metastatic cancers. Berubicin, the Company’s lead anthracycline drug candidate, is a promising treatment for glioblastoma multiforme (GBM). WPD is a biotechnology company that focuses on researching and developing medicinal products involving biological compounds and small molecules in the oncology and virology fields. WPD holds a Berubicin sublicense for the European and Asian markets.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Telehealth sector going through explosive growth; patients’ data protection remains key challenge
• Although relaxed due to COVID-19 outbreak, HIPAA guidelines protecting patients’ data security, privacy likely to tighten as pandemic abates
• RYAH appears ready to respond to strict data security requirements, uses medical data in a HIPAA-compliant setting

Telehealth is becoming increasingly popular with patients and doctors alike, but securing the integrity of patient information remains critical. As a company developing proprietary technology supporting a data-driven healthcare approach, RYAH Group appears ready to respond to the strict data security requirements.

With patients needing more access to health care, and providers and payers looking to reduce health-care costs, the use of telehealth solutions is exploding. More and more medical staff and patients alike are embracing digital healthcare options as a replacement for in-person care. Although the pandemic fuels the recent surge, the overall growth is not likely to stop once the pandemic tails off. For example, the global telemedicine market is expected to exceed $130.5 billion by 2025, with the U.S. telemedicine market expected to surpass $64.1 billion by 2025 (https://ibn.fm/AVY0p).

The technologies that power telemedicine growth are big data analytics and cloud computing. The enormous amount of data generated by devices such as smartphones, monitoring technologies, wearables and online video conferencing has opened up a world of opportunities that allows information sharing and superior analytics. Only two barriers impede the widespread adoption of big data and cloud computing in telemedicine: data privacy and security. If these critical aspects are addressed, the power of the novel technology can be harnessed to its true potential (https://ibn.fm/YRVm3).

Both patients and medical professionals are becoming accustomed to communicating through electronic devices. Although telehealth brings immense benefits, especially during the pandemic, it creates risks that must be addressed. For example, it opens up opportunities for patients’ information to fall into the wrong hands, either by accidental or malicious intent. Transmitting protected health information through unencrypted, unsecured platforms may expose protected health information.

The Health Insurance Portability and Accountability Act of 1996 (HIPAA) is the U.S. legislation designed to ensure that medical providers provide data privacy and security provisions for safeguarding their patient’s medical data. Although HIPAA guidelines are temporarily relaxed during the pandemic, this flexibility is not likely to remain as the pandemic subsides. Therefore, it is critical for health-care providers to use secure, HIPAA-compliant digital infrastructure to protect both themselves and patients at risk.

Unified data management is critical to ensuring that the right users have access to the right health-care data at the right time and in the right format. It allows health-care providers to have meaningful use of their data assets. Integrated data management, along with a formal data governance program, ensures data quality and trust in the data integrity.

As a company focused on the use of health devices, RYAH and its business model is founded on data and data management. RYAH leverages HIPAA-compliant medical data, fueling complex artificial intelligence algorithms to empower personalized treatment plans based on collective information.

For more information, visit the company’s website at www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

• Medical College of Georgia research shows beneficial effects from use of CBD oil to treat COVID-19 symptoms
• CBD oil found to increase apelin levels in the human body, a key peptide needed to reduce lung inflammation resulting from COVID-19
• PacRoots Cannabis specializes in developing premium quality strains, including plants with high CBD content, rare terpene contents, which could potentially be used for medicinal purposes

Pac Roots Cannabis (CSE: PACR) (OTCQB: PACRF) has developed a strong reputation within the global cannabis sector for producing premium quality strains and products through the employment of a meticulous, genetics-focused approach towards harvesting its crops. Following a remarkable study into the potential beneficial effects of CBD oil, the Canada-based cannabis manufacturer may potentially find itself at the forefront in the development of a remedial drug in the battle against COVID-19 (https://ibn.fm/BE8y1). Cytokine, a type of protein secreted by immune cells in response to inflammation and infection, has been found to regulate the maturation, growth, and responsiveness of particular cell populations – thereby playing an important role in the human body’s immune systems. However, an overactive cytokine response resulting from a potentially acute case of COVID-19 could also result in severe patient lung damage and, in certain cases, even lead to death. Researchers have found that a naturally occurring peptide called Apeline, which is traditionally produced in the heart, lungs, brain and blood and works as a key regulator in helping to normalize blood pressure and inflammation within the human body, may act as a suitable foil to cytokine. A recently published study carried out by scientists at the Medical College of Georgia and Dental College of Georgia (https://ibn.fm/QxEg9) found that CBD oil was shown to habitually increase apelin levels, in addition to improving blood oxygen content and reducing inflammation – and thus, the lung damage incurred through cytokine activity. In the study, scientists investigated a disease called adult respiratory distress syndrome (“ARDS”), the effects of which can result in similar lung tissue damage to that seen in severe COVID-19 cases. In the studies, blood levels of apelin were found to drop to almost zero in the midst of the disease but increased nearly twenty-fold when CBD was administered. “CBD almost brought it back to a normal level,” stated Dr Jack Yu from the Medical College of Georgia when elaborating on the effects of CBD usage on apelin levels present in the human bloodstream. While researchers were cautious on the study’s results given the need for further in-depth research into the field, it was evident that there was a strong existing correlation between ARDS and the role of apelin in reversing lung tissue damage, as well as the benefits of increasing apelin levels through CBS treatment (https://ibn.fm/IgBvn). Pac Roots Cannabis has been a pioneer within the cannabis sector in terms of improving and modifying the genetic make-up of their cannabis product, most recently through a strategic licensing agreement with Phenome Once Corp. The agreement granted Pac Roots access to one of Canada’s largest live genetic cannabis libraries with lab and field-tested, selectively bred seedlings. The Company has employed these to grow, breed and clone its own unique brands. The tie-up has enabled Pac Roots to offer its customers a remarkable portfolio of over 350 meticulously designed cultivars, including CBD-dominant plants possessing rare terpene profiles. Due to its specialty CBD plant offerings, Pac Roots appears well positioned to benefit from CBD’s positive effects on assuaging COVID-19 complications. For more information, visit the company’s website at www.PacRoots.ca. NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR

• Microcap stocks outperforming 2020 record highs, currently trading at 40% above 200-day moving average
• SRAX’s Sequire SaaS platform provides public companies with tools to monitor trading activity, provides actionable insights for use in marketing campaigns
• Sequire subscriber base surged to 3 million active traders across 90 public companies since its 2019 inception

Investor interest sent microcap stocks sky-high in 2020, a trend that is continuing well into 2021 with returns on some microcap ETFs surging at several times the rate of comparable large-cap ETFs (https://ibn.fm/Bu86D). As the tide of investor interest continues to flow into microcaps, public companies are leveraging the power of data through Sequire, SRAX’s (NASDAQ: SRAX) investor analytics SaaS platform that unlocks data and insights critical to targeted marketing campaigns in order to engage current traders and attract new investors.

Small caps – companies generally valued between $50 and $300 million – are typically thought to be more volatile and riskier when compared to established companies. Throughout 2020 and so far in 2021, that risk has paid off for investors willing to take a chance on new companies – particularly those included by SRAX subsidiary LD Micro in its North American microcap index which comprises nearly 1200 companies over 14 sectors (https://ibn.fm/m58cx).

“I cannot believe what I’ve seen in the past year,” said LD Micro President Chris Lahiji. “The LD Micro Index has more than tripled from its March 2020 lows. The tiniest public companies were also some of the biggest winners last year, and already year-to-date.”

After surging 20% in 2020, the Russell 2000 continues to outperform its historic highs and is now trading at 40% above its 200-day moving average as retail traders flood the market amid low interest rates and increased fiscal stimulus. The resulting investor interest has left many public companies looking for insights into trading activity to facilitate communications and gauge investor sentiment.

Sequire provides clarity for public companies via access to tools which help them monitor shareholder buying and selling activity while tracking key investors and outstanding warrants. The service also features applications that allow subscribers to publish company-specific news and obtain stakeholder opinions through customized surveys. The platform has experienced staggering growth since its 2019 inception to include over 3 million active retail investors across 90+ public companies (https://ibn.fm/sPoOj).

“We have been discussing the importance of retail investors in public companies since the inception of Sequire,” said SRAX CEO and Founder Christopher Miglino. “It’s the very reason why we built the platform and related tools – to help companies effectively communicate with these investors.”

As the importance of data increases across the digital landscape, SRAX maintains its commitment to build the largest and most reliable opted-in data sets across a broad range of industry verticals. Through its specialized suite of applications and tools, the Company focuses on providing brands and companies across the CPG, luxury, lifestyle and financial spaces with high-quality data that provides critical, actionable insights integral to strategic marketing campaigns.

For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Adelia Therapeutics has achieved earn-out milestones outlined in contribution agreement with Cybin
• Adelia ideal acquisition for Cybin, as it leads innovation in researching psychedelic treatment options in the mental health space
• Acquisition results in Cybin obtaining extensive intellectual property portfolio and product pipeline

Cybin (NEO: CYBN) (OTC: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, has announced that its recently acquired subsidiary, Adelia Therapeutics Inc., has achieved the earn-out milestones outlined for the time period in the contribution agreement between the two companies (https://ibn.fm/c6o2E). That milestone includes the successful synthesis of multiple tryptamine derivatives.

Furthermore, the synthesis of tryptamine derivatives resulted in quantities adequate enough that Adelia could initiate in vitro “Proof of Principle”; establish that an ADME/PK has been completed; and demonstrate “In Vitro” ADME “Proof of Principle” that specific synthesis modifies the metabolism of a psychedelic tryptamine.

Adelia focuses on developing medicinal psychedelics with improved dosing efficacy and therapeutic indices to address unmet medical needs, which makes the company an idea fit for Cybin, as it leads the way in researching psychedelic treatment options in the mental health space. Adelia’s proprietary development strategy is based on chemical modifications to already known tryptamine derivatives that significantly alter the pharmacokinetic properties of those derivatives without changing their therapeutic potential. The company’s recent milestone is a direct result of this focus and its dedication to seeking to minimize inter-patient variability by better controlling drug metabolism without loss of efficacy.

Cybin’s acquisition of Adelia resulted in Cybin obtaining an extensive intellectual property portfolio and product pipeline that could lead to diversification beyond major depressive disorder (“MDD”) treatments and regimens. Adelia’s three-pillar development strategy includes novel therapeutics, delivery methods and therapeutic regimens focused on improving patient outcomes. The acquisition also results in Cybin gaining psychedelic derivative drug-development candidates, with the first lead compounds expected to enter clinical studies in 2021.

“We are thrilled to join forces with Adelia,” said Cybin CEO Doug Drysdale when announcing the acquisition (https://ibn.fm/T5eIg). “We see this acquisition as potentially advancing Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder. Adelia’s focuses on novel delivery methods and innovative therapies may contribute to our goal of therapies with faster onset of action, smoother pharmacokinetic profiles, shorter treatment periods, and reduced side effects. Adelia’s expertise across multiple molecules and multiple indications, could potentially give Cybin the ability to address gaps across a larger domain.”

The Adelia acquisition also combines two talented teams that share strong patient-first values and track records of innovation in the field of psychedelics. Adelia’s leadership team of accomplished scientists brings invaluable preclinical development experience that complements Cybin’s clinical experience and resources.

Cybin is a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions. Cybin is developing technologies and delivery systems, aiming to improve bioavailability, to potentially achieve the desired medicinal effects of psychedelics at low dosage levels. The new delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• BRSF working to improve diagnostics by leveraging AI and machine learning
• Cloud-based infrastructure, AI-assisted diagnostic analysis is in development phase
• Brain Scientific creating long-term monitoring capabilities that leads to collection of essential biomarkers

Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company focused on developing innovative and proprietary medical devices and software, is working on developing state-of-the-art AI diagnostic analytics. The company’s two FDA-cleared products — the NeuroCap(TM) and NeuroEEG(TM) — offer cost-effective disposable alternatives to existing electroencephalogram (“EEG”) solutions. These disposable and simple-to-use devices allow medical professionals to collect necessary diagnostic information quickly.

But BRSF isn’t stopping there.

The company’s goal is to further improve diagnostics by leveraging artificial intelligence (“AI”) and machine learning processes to analyze a database of brain readings to improve diagnosis and treatment of neurological conditions.

The company is using in-house development in order to provide diagnostic interpretation assistance for health-care providers. Currently, a secure cloud-based infrastructure and AI-assisted diagnostic analysis are in the development phase.

BRSF’s remote diagnostic devices that are already in active use will be used to acquire large datasets of neurological information that will be uploaded to the company’s secure cloud technology. These neural networks of data will be used to identify patterns and biomarkers for neurological disease in the near future. Eventually, this data will be integrated with external graph datasets that contain neurological clinical and research data. When that happens, the neural networks will comb the data to detect patterns. Over time the AI will be able to make predictions that will aid neurologists and increase access to complex neuro-diagnostic expertise (https://ibn.fm/3V7Wx).

As more clinical trials and studies are done on neurological conditions, additional data is acquired. On the Neuroscience Information Framework (“NIF”), there are currently over 4,000 databases of neurological information (https://ibn.fm/7pKza). No single neurologist can attempt to evaluate that much data to discover the best treatment for the one patient under their care.

But a computer can. By creating a secure cloud of BRSF’s data that can be integrated with external datasets and using AI with machine learning to filter through the data, neurologists will be able to locate the information needed to best help their patients. The implications of this technology is huge.

An article in Forbes states that “Biomarkers of Longevity integrated with AI and machine learning techniques have the potential to help prevent age-related diseases and extend health span,” reported a “Forbes” artice (https://ibn.fm/s5MWM). “Advances in the development of biomarkers will allow doctors to assess health, quantify the effect of interventions, and produce personalized medical reports.”

Big data plus AI will make neurological care accessible in a way it has not yet been, and BRSF committed to help pave the way.

To learn more about this company, visit www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Asia Broadband Inc. is focused on the production, supply and sale of precious and base metals, primarily to Asian markets
• The company recently acquired a high potential mineral property in the state of Colima, Mexico
• Asia Broadband has teamed with crypto wallet creator Core State Holdings Corp. to develop the AABB Gold token, a gold-backed cryptocurrency coin
• On February 25, 2021, Asia Broadband announced management and board approval of a stock dividend for shareholders

Asia Broadband (OTC: AABB) is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian markets. The company utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate its innovative distribution process from the production and supply of precious and base metals in Mexico to client sales networks in Asia. This vertically integrated approach to sales transactions differentiates Asia Broadband from its competitors in the mining space. Development Program in Colima, Mexico In October 2020, Asia Broadband announced its acquisition of a high potential mineral property in the state of Colima, Mexico. Per the press release, previous geophysics and groundwork have revealed strong indications of significant mineralization in multiple sectors of the property. The company recently began the construction of exploration and development facilities and infrastructure roads on its Colima property, and plans are underway to extend previous geophysics and groundwork on the property. In January 2021, Asia Broadband announced its allocation of $10 million for the initial development program, with the aim of accelerating operations at the Colima site toward production. Positioned in a major gold-iron-copper production area, the company’s Colima property is situated approximately 25 kilometers east of the Pena Colorada mine in Minatitlan, Mexico. It is advantageously located, with direct access to main Highway #3, and the property also has an essential natural water supply. AABB Gold Token In December 2020, Asia Broadband announced its entry into a definitive development agreement with Core State Holdings Corp., a digital assets and crypto wallet creator, to produce a white label gold-backed cryptocurrency coin. The AABB Gold token is an ERC-20 token being developed on the Ethereum blockchain. In a February 2021 news release, the company provided a development update on the cryptocurrency token, noting that Core State Holdings Corp. “is continuing to modify the set-up and move through the final stages of testing of the iOS and Android AABB Wallet applications, including the implementation of an application interface to allow users to see the real-time exchange rate of gold that backs the price of the AABB Gold token set at one-tenth of a gram or approximately $5.80 USD.” Core State Holdings Corp. has also continued to enhance www.AABBGoldToken.com, which the company notes will be the go-to knowledge base for all information concerning the soon-to-be launched AABB Wallet and AABB Gold token. AABB’s primary goal for the token is to become a worldwide standard of exchange – secured and trusted with gold backing – by expanding circulation and targeting large population and high growth markets globally, including China and East Asia. For more information, visit the company’s website at www.AsiaBroadbandInc.com. NOTE TO INVESTORS: The latest news and updates relating to AABB are available in the company’s newsroom at https://ibn.fm/AABB